X4 Investor Day: 4WARD Enrollment Due Q4 2026, Topline Q1 2028, ~15K-Patient PCN Base Case
XFOR sits 42% above its 52-week low of $2.43.
Summary
X4's Investor Day deck lays out the 4WARD Phase 3 baseline data, a ~15,000-patient US base case for mavorixafor in primary chronic neutropenia, and a timeline of full enrollment by Q4 2026 with topline data in Q1 2028.
Key Events · Product Development and Regulatory · XFOR
-
Investor Day Deck Details 4WARD Baseline
Blinded pooled data as of September 2026: median age 36, 70% female, median baseline ANC 483 cells/µL, 68% of patients with 3+ infections at baseline, 37% on concurrent G-CSF.
-
PCN Market Sized at ~15,000 Base Case
US symptomatic patients with ANC <1,000 cells/µL and 2+ infections total ~15,000; 1+ infections ~30,000; ~95,000 diagnosed age 12+ including asymptomatic.
-
Timeline: Enrollment Q4 2026, Data Q1 2028
Full 4WARD enrollment (N=126) expected end of Q4 2026, topline Q1 2028, potential FDA approval late 2028/early 2029; 4STEPS Phase 2b starts Q1 2027 with data H1 2028.
-
Cash Runway Reiterated Into 2029
Presentation states cash runway expected into 2029, covering the 4WARD topline readout; forward-looking statements flag the need for additional capital and K2HV loan covenant compliance as risks.
Analysis · XFOR · Life Sciences
The 8-K is merely a notice that the Investor Day deck has been posted, but the deck itself provides the first hard look at the 4WARD Phase 3 baseline and the commercial opportunity. Blinded pooled data depict a sick population—median baseline ANC of 483 cells/µL and 68% of patients with three or more prior infections—which supports the trial's infection-rate endpoint. Management also sized the US opportunity at roughly 15,000 symptomatic patients with two or more infections, with about 30,000 at one or more. Against that, the timeline is long: full enrollment of 126 patients by end of Q4 2026, topline in Q1 2028, and potential approval in late 2028 or early 2029. The 4STEPS G-CSF dose-reduction study starts in Q1 2027 with data in H1 2028. Cash runway is reiterated into 2029, so the company says it is funded through the 4WARD readout—the key thing that would change the story is any slip in that enrollment or data timeline.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XFOR was trading at $3.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $341.1M. The 52-week trading range was $2.43 to $4.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.